{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:34:32Z","timestamp":1772184872755,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T00:00:00Z","timestamp":1568419200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T00:00:00Z","timestamp":1568419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10198-019-01110-w","type":"journal-article","created":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T12:02:31Z","timestamp":1568462551000},"page":"45-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis"],"prefix":"10.1007","volume":"21","author":[{"given":"Axel","family":"Svedbom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Dal\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moa","family":"Iverg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebekah H.","family":"Borse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Luttropp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumesh","family":"Kachroo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,14]]},"reference":[{"key":"1110_CR1","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/ard.2004.029728","volume":"64","author":"A Wanders","year":"2005","unstructured":"Wanders, A., Landewe, R., Dougados, M., Mielants, H., van der Linden, S., van der Heijde, D.: Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann. Rheum. Dis. 64, 988\u2013994 (2005)","journal-title":"Ann. Rheum. Dis."},{"key":"1110_CR2","first-page":"102","volume":"44","author":"JF Fries","year":"1996","unstructured":"Fries, J.F.: Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. J. Rheumatol. Suppl. 44, 102\u2013106 (1996)","journal-title":"J. Rheumatol. Suppl."},{"key":"1110_CR3","doi-asserted-by":"publisher","first-page":"e0126105","DOI":"10.1371\/journal.pone.0126105","volume":"10","author":"R Cooksey","year":"2015","unstructured":"Cooksey, R., Husain, M.J., Brophy, S., Davies, H., Rahman, M.A., Atkinson, M.D., Phillips, C.J., Siebert, S.: The cost of ankylosing spondylitis in the UK using linked routine and patient-reported survey data. PLoS One 10, e0126105 (2015)","journal-title":"PLoS One"},{"key":"1110_CR4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean, L.E., Jones, G.T., MacDonald, A.G., Downham, C., Sturrock, R.D., Macfarlane, G.J.: Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 53, 650\u2013657 (2014)","journal-title":"Rheumatology (Oxford)"},{"key":"1110_CR5","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.clinthera.2011.06.001","volume":"33","author":"MA Blum","year":"2011","unstructured":"Blum, M.A., Koo, D., Doshi, J.A.: Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin. Ther. 33, 901\u2013913 (2011)","journal-title":"Clin. Ther."},{"issue":"6","key":"1110_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde, D., Ramiro, S., Landew\u00e9, R., Baraliakos, X., Van den Bosch, F., Sepriano, A., Regel, A., Ciurea, A., Dagfinrud, H., Dougados, M.: 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 76(6), 978\u2013991 (2017). (Annrheumdis-2016-210770)","journal-title":"Ann. Rheum. Dis."},{"key":"1110_CR7","first-page":"523","volume":"55","author":"A Souto","year":"2015","unstructured":"Souto, A., Maneiro, J.R., G\u00f3mez-Reino, J.J.: Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology 55, 523\u2013534 (2015)","journal-title":"Rheumatology"},{"key":"1110_CR8","first-page":"1631","volume":"29","author":"D Aletaha","year":"2002","unstructured":"Aletaha, D., Smolen, J.S.: Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol. 29, 1631\u20131638 (2002)","journal-title":"J Rheumatol."},{"key":"1110_CR9","first-page":"1885","volume":"19","author":"T Pincus","year":"1992","unstructured":"Pincus, T., Marcum, S.B., Callahan, L.F.: Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J. Rheumatol. 19, 1885\u20131894 (1992)","journal-title":"J. Rheumatol."},{"key":"1110_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell, P.M.: External validity of randomised controlled trials:\u201cto whom do the results of this trial apply?\u201d. Lancet 365, 82\u201393 (2005)","journal-title":"Lancet"},{"issue":"4","key":"1110_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/annrheumdis-2017-212423","volume":"77","author":"S Henaux","year":"2017","unstructured":"Henaux, S., Ruyssen-Witrand, A., Cantagrel, A., Barnetche, T., Fautrel, B., Filippi, N., Lukas, C., Raffeiner, B., Rossini, M., Degbo\u00e9, Y.: Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann. Rheum. Dis. 77(4), 515\u2013522 (2017). (Annrheumdis-2017-212423)","journal-title":"Ann. Rheum. Dis."},{"key":"1110_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2010.131797","volume":"70","author":"E Lie","year":"2011","unstructured":"Lie, E., van der Heijde, D., Uhlig, T., Mikkelsen, K., Rodevand, E., Koldingsnes, W., Kaufmann, C., Kvien, T.K.: Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann. Rheum. Dis. 70, 157\u2013163 (2011)","journal-title":"Ann. Rheum. Dis."},{"key":"1110_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1524-4733.2007.00205.x","volume":"10","author":"D Hughes","year":"2007","unstructured":"Hughes, D., Cowell, W., Koncz, T., Cramer, J.: Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value health 10, 498\u2013509 (2007)","journal-title":"Value health"},{"key":"1110_CR14","unstructured":"NICE (2016) Single Technology Appraisal. Secukinumab for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy [ID719]\u2014Committee papers. National Institute for Health and Care Excellence, UK. \nhttps:\/\/www.nice.org.uk\/guidance\/ta407\/documents\/committee-papers\n\n. Accessed 12 Sept 2019"},{"key":"1110_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20090","volume":"20","author":"M Corbett","year":"2016","unstructured":"Corbett, M., Soares, M., Jhuti, G., et al.: Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol. Assess. 20, 1\u2013334 (2016). (v-vi)","journal-title":"Health Technol. Assess."},{"key":"1110_CR16","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3899\/jrheum.150389","volume":"42","author":"AV Heinonen","year":"2015","unstructured":"Heinonen, A.V., Aaltonen, K.J., Joensuu, J.T., Lahteenmaki, J.P., Pertovaara, M.I., Romu, M.K., Hirvonen, H.E., Simila, A.K., Blom, M.L., Nordstrom, D.C.: Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study. J. Rheumatol. 42, 2339\u20132346 (2015)","journal-title":"J. Rheumatol."},{"key":"1110_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3904\/kjim.2016.042","volume":"33","author":"H Jeong","year":"2018","unstructured":"Jeong, H., Eun, Y.H., Kim, I.Y., Kim, H., Ahn, J.K., Lee, J., Koh, E.M., Cha, H.S.: Drug survival of tumor necrosis factor alpha inhibitors in patients with ankylosing spondylitis in Korea. Korean J. Intern. Med. 33, 407\u2013416 (2018)","journal-title":"Korean J. Intern. Med."},{"key":"1110_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/03009742.2017.1330419","volume":"47","author":"J Ruwaard","year":"2018","unstructured":"Ruwaard, J., l\u2019Ami, M.J., Marsman, A.F., Kneepkens, E.L., van Denderen, J.C., van der Horst-Bruinsma, I.E., Nurmohamed, M.T., Wolbink, G.: Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab. Scand. J. Rheumatol. 47, 122\u2013126 (2018)","journal-title":"Scand. J. Rheumatol."},{"key":"1110_CR19","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1136\/ard.2011.151191","volume":"70","author":"G Bakland","year":"2011","unstructured":"Bakland, G., Gran, J.T., Nossent, J.C.: Increased mortality in ankylosing spondylitis is related to disease activity. Ann. Rheum. Dis. 70, 1921\u20131925 (2011)","journal-title":"Ann. Rheum. Dis."},{"key":"1110_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","volume":"73","author":"J Braun","year":"2014","unstructured":"Braun, J., Baraliakos, X., Hermann, K.G., Deodhar, A., van der Heijde, D., Inman, R., Beutler, A., Zhou, Y., Xu, S., Hsu, B.: The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4\u00a0years of the GO-RAISE trial. Ann. Rheum. Dis. 73, 1107\u20131113 (2014)","journal-title":"Ann. Rheum. Dis."},{"key":"1110_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","volume":"77","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde, D., Baraliakos, X., Hermann, K.-G.A., Landew\u00e9, R.B., Machado, P.M., Maksymowych, W.P., Davies, O.R., de Peyrecave, N., Hoepken, B., Bauer, L.: Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann. Rheum. Dis. 77, 699\u2013705 (2018)","journal-title":"Ann. Rheum. Dis."},{"key":"1110_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-eular.1396","volume-title":"SAT0268 Secukinumab demonstrates low radiographic progression and sustained efficacy through 4\u00a0years in patients with active ankylosing spondylitis","author":"X Baraliakos","year":"2018","unstructured":"Baraliakos, X., Braun, J., Deodhar, A., Poddubny, D., Emery, P., Delicha, E., Talloczy, Z., Porter, B.: SAT0268 Secukinumab demonstrates low radiographic progression and sustained efficacy through 4\u00a0years in patients with active ankylosing spondylitis. BMJ Publishing Group Ltd, London (2018)"},{"key":"1110_CR23","unstructured":"NICE (2016) TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. Technology appraisal guidance TA383, National Institute for Health and Care Excellence, UK. \u200b\nhttps:\/\/www.nice.org.uk\/guidance\/ta383\n\n. Accessed 12 Sept 2019"},{"key":"1110_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2015.02.016","volume":"18","author":"A Wailoo","year":"2015","unstructured":"Wailoo, A., Hernandez, M., Philips, C., Brophy, S., Siebert, S.: Modeling health state utility values in ankylosing spondylitis: comparisons of direct and indirect methods. Value Health 18, 425\u2013431 (2015)","journal-title":"Value Health"},{"key":"1110_CR25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/ard.62.8.732","volume":"62","author":"A Boonen","year":"2003","unstructured":"Boonen, A., van der Heijde, D., Landewe, R., et al.: Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann. Rheum. Dis. 62, 732\u2013740 (2003)","journal-title":"Ann. Rheum. Dis."},{"key":"1110_CR26","first-page":"246","volume":"30","author":"R Rafia","year":"2012","unstructured":"Rafia, R., Ara, R., Packham, J., Haywood, K.L., Healey, E.: Healthcare costs and productivity losses directly attributable to ankylosing spondylitis. Clin. Exp. Rheumatol. 30, 246\u2013253 (2012)","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1\u2013158","key":"1110_CR27","first-page":"3","volume":"11","author":"C McLeod","year":"2007","unstructured":"McLeod, C., Bagust, A., Boland, A., Dagenais, P., Dickson, R., Dundar, Y., Hill, R.A., Jones, A., Mujica Mota, R., Walley, T.: Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol. Assess. 11(1\u2013158), 3\u20134 (2007)","journal-title":"Health Technol. Assess."},{"key":"1110_CR28","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s12325-016-0371-0","volume":"33","author":"GW Cannon","year":"2016","unstructured":"Cannon, G.W., DuVall, S.L., Haroldsen, C.L., et al.: Clinical outcomes and biologic costs of switching between tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. Adv Ther 33, 1347\u20131359 (2016)","journal-title":"Adv Ther"},{"key":"1110_CR29","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00296-017-3825-z","volume":"37","author":"J Dalen","year":"2017","unstructured":"Dalen, J., Svedbom, A., Black, C.M., Kachroo, S.: Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors. Rheumatol. Int. 37, 2049\u20132058 (2017)","journal-title":"Rheumatol. Int."},{"key":"1110_CR30","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00296-016-3423-5","volume":"36","author":"J Dalen","year":"2016","unstructured":"Dalen, J., Svedbom, A., Black, C.M., Lyu, R., Ding, Q., Sajjan, S., Sazonov, V., Kachroo, S.: Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol. Int. 36, 987\u2013995 (2016)","journal-title":"Rheumatol. Int."},{"key":"1110_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3111\/13696998.2016.1142448","volume":"19","author":"N Rashid","year":"2016","unstructured":"Rashid, N., Lin, A.T., Aranda Jr., G., Lin, K.J., Guerrero, V.N., Nadkarni, A., Patel, C.: Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system. J. Med. Econ. 19, 568\u2013575 (2016)","journal-title":"J. Med. Econ."},{"key":"1110_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/PPA.S119808","volume":"11","author":"A Svedbom","year":"2017","unstructured":"Svedbom, A., Dalen, J., Black, C.M., Kachroo, S.: Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line. Patient Prefer. Adherence 11, 95\u2013106 (2017)","journal-title":"Patient Prefer. Adherence"},{"key":"1110_CR33","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3899\/jrheum.080871","volume":"36","author":"X Baraliakos","year":"2009","unstructured":"Baraliakos, X., Listing, J., von der Recke, A., Braun, J.: The natural course of radiographic progression in ankylosing spondylitis\u2014evidence for major individual variations in a large proportion of patients. J. Rheumatol. 36, 997\u20131002 (2009)","journal-title":"J. Rheumatol."},{"issue":"Suppl 1","key":"1110_CR34","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1007\/s10198-014-0598-0","volume":"15","author":"K Gulyas","year":"2014","unstructured":"Gulyas, K., Bodnar, N., Nagy, Z., et al.: Real-life experience with switching TNF-alpha inhibitors in ankylosing spondylitis. Eur. J. Health Econ. 15(Suppl 1), S93\u2013S100 (2014)","journal-title":"Eur. J. Health Econ."},{"key":"1110_CR35","first-page":"50","volume":"50","author":"MA Machado","year":"2016","unstructured":"Machado, M.A., Moura, C.S., Ferre, F., Bernatsky, S., Rahme, E., Acurcio Fde, A.: Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis. Rev. Saude Publica 50, 50 (2016)","journal-title":"Rev. Saude Publica"},{"key":"1110_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2217\/cer-2017-0076","volume":"7","author":"JA Walsh","year":"2018","unstructured":"Walsh, J.A., Adejoro, O., Chastek, B., Park, Y.: Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. J. Comp. Eff. Res. 7, 369\u2013380 (2018)","journal-title":"J. Comp. Eff. Res."},{"key":"1110_CR37","doi-asserted-by":"publisher","first-page":"e000596","DOI":"10.1136\/rmdopen-2017-000596","volume":"4","author":"KM Fagerli","year":"2018","unstructured":"Fagerli, K.M., Kearsley-Fleet, L., Watson, K.D., Packham, J., Contributors Group BR, Symmons, D.P.M., Hyrich, K.L.: Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. RMD Open 4, e000596 (2018)","journal-title":"RMD Open"},{"key":"1110_CR38","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L., Torrance, G.W.: Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford (2015)"},{"key":"1110_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0167-6296(94)00044-5","volume":"14","author":"MA Koopmanschap","year":"1995","unstructured":"Koopmanschap, M.A., Rutten, F.F., van Ineveld, B.M., Van Roijen, L.: The friction cost method for measuring indirect costs of disease. J. Health. Econ. 14, 171\u2013189 (1995)","journal-title":"J. Health. Econ."},{"key":"1110_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00019053-199813010-00001","volume":"13","author":"B Liljas","year":"1998","unstructured":"Liljas, B.: How to calculate indirect costs in economic evaluations. Pharmacoeconomics 13, 1\u20137 (1998)","journal-title":"Pharmacoeconomics"},{"key":"1110_CR41","unstructured":"NICE (2014) Interim methods guide for developing service guidance 2014. Process and methods guides no. 8. National Institute for Health and Care Excellence (NICE),  London. \nhttps:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28230952\n\n \u00a0"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-019-01110-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-019-01110-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-019-01110-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T23:16:34Z","timestamp":1599952594000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-019-01110-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,14]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1110"],"URL":"https:\/\/doi.org\/10.1007\/s10198-019-01110-w","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,14]]},"assertion":[{"value":"4 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no other conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was supported by Merck & Co., Inc. S Kachroo, C Black, and R Borse are employees of Merck & Co., Kenilworth, NJ, USA, and hold stock and options. A Svedbom, J Dal\u00e9n, M Iverg\u00e5rd, and K Luttropp were paid consultants to Merck through their employment at ICON Clinical Research. ICON Clinical Research has received funding from several pharmaceutical companies involved in the marketing of products for treatment of rheumatic disease.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study was supported by Merck & Co., Inc. Given that the work relies on synthesis of publically available data, the research did not involve human participants and\/or animals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}]}}